+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results



Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results



Transplantation Proceedings 24(5): 1732-1733




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 041102787

Download citation: RISBibTeXText

PMID: 1412815


Related references

Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. Transplantation Proceedings 29(7): 2955-2957, 1997

Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients. Transplantation Proceedings 29(7a): 32s-34s, 1997

OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplantation Proceedings 27(1): 852-853, 1995

Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 60(11): 1357-1360, 1995

Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. American Journal of Kidney Diseases 14(5 Suppl 2): 14-18, 1989

A prospective clinical trial comparing low dose OKT3 prophylaxis and prednisolone cyclosporine treatment in renal transplant recipients. Kidney International 43(4): 971-972, 1993

Comparison of prophylactic OKT3 versus ATG in immunologic high risk cadaver renal transplant recipients. Journal of the American Society of Nephrology 6(3): 1084, 1995

Long-term results of OKT3-treated renal transplant recipients. Transplantation Proceedings 28(3): 1350-1351, 1996

Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients. Transplantation Proceedings 28(5): 2808-2809, 1996

Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Journal of the American Society of Nephrology 16(8): 2509-2516, 2005

Risk factors for symptomatic cytomegalovirus cmv infection in cadaveric renal transplant recipients randomized to either anti lymphoblast globulin or anti t3 antibody okt3 for rejection prophylaxis. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 294, 1991

FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Transplantation Proceedings 28(6): 3166-3168, 1996

Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. American Journal of Kidney Diseases 21(2): 196-201, 1993

Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients. Transplant International 15(11): 550-555, 2002

The risk of infection following Okt3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial. Transplant International 5: S440-S443, 1992